Abstract Library

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,

#4642 Establishing a standardised histopathological grading system for mesenteric fibrosis in small intestinal neuroendocrine tumours

Introduction: Mesenteric fibrosis (MF) frequently develops around mesenteric metastasis in small intestinal neuroendocrine tumour (SI-NET) patients. Since MF is not always detected radiologically, histopathological examination is considered the gold standard. However, there is no uniform histopathological scoring system for MF correlated with clinical data.

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, Hofland L, Hall A, Iyer A,

Keywords: small intestinal neuroendocrine tumour, mesenteric fibrosis, grading system,

#4546 Epigenetic exploration of mesenteric fibrosis indicates epigenetic disruption of DAXX is driving metastatic potential in small intestinal neuroendocrine tumours

Introduction: Up to 50% of patients diagnosed with small intestinal neuroendocrine tumours (SI-NETs) are affected by mesenteric fibrosis (MF) which has significant pathological effects and impacts patient mortality.

Conference:

Presenting Author: Webster A

Authors: Webster A, Martins M, Hodgetts H, Feelders R, Hofland L,

Keywords: DNA methylation, SI-NET, Mesenteric fibrosis, Epigenetics, Gene regulation, DAXX,

#4085 Disease-specific mortality in a single-center cohort of 427 patients with carcinoid syndrome

Introduction: The carcinoid syndrome (CS), the most prevalent hormonal syndrome in patients with a neuroendocrine tumor (NET), is associated with impaired survival. Due to the biological behaviour of NET and overall improvement in survival rates, patients with CS may not succumb to their disease. However, the contribution of NET-specific death in these patients is currently unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Feelders R, de Herder W, Hofland J,

Keywords: carcinoid syndrome, neuroendocrine tumor, prognosis, survival analysis,

#4017 Serum 5-hydroxyindoleacetic acid is equivalent to 24-hour urinary 5-hydroxyindoleacetic acid for the diagnosis of carcinoid syndrome

Introduction: Neuroendocrine tumors (NET) are characterized by their ability to secrete amines and peptides. Overproduction of serotonin results in the carcinoid syndrome (CS), present in approximately 20% of all NET patients. Measuring the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in 24-hour urine is frequently used for the diagnosis and follow-up of CS patients. However, these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might be a more reliable and convenient alternative in the diagnosis of CS.

Conference:

Presenting Author:

Authors: Kerolles M, Mulders M, Mirzaian M, van den Berg S, Feelders R,

Keywords: 5-hiaa, carcinoid syndrome, neuroendocrine tumor, biomarker,